The reaffirmation of a Sell rating by a major analyst like Goldman Sachs typically indicates a bearish outlook on the stock, which could lead to a negative short-term impact on HRMY's stock price. However, the increase in the price target from $25 to $28 suggests a less negative outlook than before, which might mitigate the impact slightly.